Winton Group LTD Alnylam Pharmaceuticals, Inc. Transaction History

Winton Group LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$146.51 - $198.2 $215,516 - $291,552	1,471 New	1,471 $219,000
Q1 2023 May 12, 2023	BUY	$182.66 - $235.53 $625,610 - $806,690	3,425 New	3,425 $686,000
Q2 2022 Aug 10, 2022	SELL	$120.42 - $169.29 $366,799 - $515,657	-3,046 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$127.18 - $173.91 $387,390 - $529,729	3,046 New	3,046 $497,000
Q4 2021 Feb 10, 2022	SELL	$159.56 - $209.29 $464,479 - $609,243	-2,911 Closed	0 $0
Q3 2021 Oct 28, 2021	BUY	$169.75 - $207.73 $494,142 - $604,702	2,911 New	2,911 $550,000
Q4 2020 Feb 12, 2021	SELL	$122.97 - $147.0 $1.02 Million - $1.22 Million	-8,298 Closed	0 $0
Q3 2020 Oct 30, 2020	SELL	$121.19 - $165.49 $3.21 Million - $4.38 Million	-26,472 Reduced 76.13%	8,298 $1.21 Million
Q2 2020 Aug 05, 2020	BUY	$104.21 - $156.44 $2.69 Million - $4.03 Million	25,785 Added 286.98%	34,770 $5.15 Million
Q1 2020 May 11, 2020	BUY	$93.12 - $133.99 $836,683 - $1.2 Million	8,985 New	8,985 $978,000
Q4 2017 Feb 13, 2018	SELL	$114.49 - $139.98 $10.4 Million - $12.7 Million	-90,504 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$72.53 - $118.27 $6.56 Million - $10.7 Million	90,504	90,504 $10.6 Million

663

109M

1.28M

1.23M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $34B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.